단일염기다형성(SNP) 지노타이핑 시장 : 기술별, 용도별, 지역별(2025-2033년)

The global single nucleotide polymorphism (SNP) genotyping market size reached USD 11.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 42.3 Billion by 2033, exhibiting a growth rate (CAGR) of 15.00% during 2025-2033. The growing genotype research and development activities, rising demand for personalized medicine and novel drug delivery systems, and increasing demand for genetic analysis in animal and plant feedstock represent some of the key factors driving the market.

Single nucleotide polymorphism (SNP) genotyping is a technique designed to identify and analyze genetic variations among individuals by examining specific locations within their deoxyribonucleic acid (DNA) sequence. It involves determining the specific nucleotide present at a particular SNP site in the DNA of an individual. It relies on advanced molecular biology techniques, such as polymerase chain reaction (PCR) and DNA sequencing, wherein PCR amplifies the DNA segment containing the SNP, and then the nucleotide at the SNP site is determined either by directly sequencing the amplified DNA or using other methods like microarrays or allele-specific PCR. It aids in understanding population genetics, migration patterns, and evolutionary history. It plays a crucial role in determining response to medications, predicting disease susceptibility, and tailoring treatments to specific genetic profiles. SNP genotyping is used by researchers to study the genetic basis of complex diseases, identify genetic risk factors, and develop enhanced diagnostic tools.

Single Nucleotide Polymorphism (SNP) Genotyping Market Trends:

At present, the increasing demand for SNP genotyping on account of the rising genotype research and development activities and bioinformatics in the development of diagnostic tools or effective therapeutics for various diseases represents one of the crucial factors supporting the growth of the market. In addition, the growing utilization of SNP genotyping in the etiology of various human diseases, such as cancer, cardiovascular, Alzheimer's, and asthma, is offering a favorable market outlook. Besides this, there is a rise in the demand for SNP genotyping to establish genetic relationships, resolve paternity disputes, and assist in criminal investigations around the world. This, along with the thriving medical industry, is propelling the growth of the market. Moreover, the increasing demand for pharmacogenomics due to the rising pipeline for personalized medicine and novel drug delivery systems is strengthening the growth of the market. Apart from this, numerous technologies of SNP genotyping in the life science field, such as agricultural biotechnology, diagnostic research, pharmaceuticals, pharmacogenomics, and animal and livestock breeding, are contributing to the growth of the market. In line with this, the growing prevalence of diabetes, cardiovascular diseases, and cancer across the globe is positively influencing the market. Furthermore, the rising demand for genetic analysis in animal and plant feedstock is bolstering the growth of the market.

Key Market Segmentation:

Technology Insights:

• TaqMan SNP Genotyping
• Massarray SNP Genotyping
• SNP GeneChip Arrays
• Others

Application Insights:

• Animal Genetics
• Plant Improvement
• Diagnostic Research
• Pharmaceuticals and Pharmacogenomics
• Agricultural Biotechnology
• Others

Regional Insights:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
• The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for single nucleotide polymorphism (SNP) genotyping. Some of the factors driving the North America single nucleotide polymorphism (SNP) genotyping market included favorable government policies towards proper diagnosis, increasing screening and treatment of fatal diseases, availability of enhanced research and development (R&D) facilities, etc.

Competitive Landscape:

• The report has also provided a comprehensive analysis of the competitive landscape in the global single nucleotide polymorphism (SNP) genotyping market. Detailed profiles of all major companies have been provided. Some of the companies covered include Agilent Technologies Inc., Eurofins Genomics (Eurofins Scientific SE), Illumina Inc., Integrated DNA Technologies, Inc. (Danaher Corporation), LGC Limited, PREMIER Biosoft, Promega Corporation, QIAGEN N.V, Roche Holding AG, Thermo Fisher Scientific Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

• How has the global single nucleotide polymorphism (SNP) genotyping market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global single nucleotide polymorphism (SNP) genotyping market?
• What is the impact of each driver, restraint, and opportunity on the global single nucleotide polymorphism (SNP) genotyping market?
• What are the key regional markets?
• Which countries represent the most attractive single nucleotide polymorphism (SNP) genotyping market?
• What is the breakup of the market based on the technology?
• Which is the most attractive technology in the single nucleotide polymorphism (SNP) genotyping market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the single nucleotide polymorphism (SNP) genotyping market?
• What is the competitive structure of the global single nucleotide polymorphism (SNP) genotyping market?
• Who are the key players/companies in the global single nucleotide polymorphism (SNP) genotyping market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Single Nucleotide Polymorphism (SNP) Genotyping Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Technology

• 6.1 TaqMan SNP Genotyping
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Massarray SNP Genotyping
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 SNP GeneChip Arrays
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Application

• 7.1 Animal Genetics
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Plant Improvement
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Diagnostic Research
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Pharmaceuticals and Pharmacogenomics
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Agricultural Biotechnology
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 Drivers, Restraints, and Opportunities

• 9.1 Overview
• 9.2 Drivers
• 9.3 Restraints
• 9.4 Opportunities

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Agilent Technologies Inc.
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Eurofins Genomics (Eurofins Scientific SE)
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
  • 13.3.3 Illumina Inc.
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 Integrated DNA Technologies, Inc. (Danaher Corporation)
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
  • 13.3.5 LGC Limited
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
  • 13.3.6 PREMIER Biosoft
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
  • 13.3.7 Promega Corporation
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
  • 13.3.8 QIAGEN N.V
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Roche Holding AG
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
  • 13.3.10 Thermo Fisher Scientific Inc.
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.